返回排名列表

Cigna Group (CI)

合理估值
HealthcareHealthcare PlansUnited States

基本面

78

价格

$267.52

市值

$71.83B

第一部分 · 这家公司值多少

概览

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users

P/E: 23.6Score: 70Market cap: $336.61B

It is the closest mirror image of Cigna, selling employer-sponsored health plans to the same large US corporate clients while its Optum Rx pharmacy benefit manager bids against Evernorth's Express Scripts for the same drug-benefit contracts.

P/E: 22.6Score: 58Market cap: $112.36B

Through Aetna it competes for the same commercial and employer health members, and through CVS Caremark it is one of the three pharmacy benefit managers that split the US market with Express Scripts.

P/E: 15.7Score: 72Market cap: $85.57B

As the largest Blue Cross Blue Shield operator it bids for the same employer and individual health plans in overlapping US states, and its CarelonRx unit competes directly with Evernorth on pharmacy benefits.

P/E: —Score: 53Market cap: $30.89B

It is the biggest insurer on the US individual insurance marketplaces, where it competes with Cigna Healthcare for the same subsidised individual customers state by state.

Health Care Service CorporationNot tracked

This mutual Blue Cross insurer covering Illinois, Texas and three other states is the fifth-largest US commercial carrier and now also owns the Medicare business Cigna sold it in March 2025, putting the two head to head on national employer accounts.

资产负债表与流动性

营收

$282.38B

最近12个月(截至2026/6/30)

净利润

$6.42B

最近12个月(截至2026/6/30)

自由现金流

-

股东权益合计

$41.71B

负债合计

$116.05B

流动比率

0.85

利息覆盖率

7.03

债务/EBITDA

2.75

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形合理估值

公允价值

$324.54

当前价格

$267.52

安全边际

+17.6%

公允价值区间

$210.95 - $438.13

所用估值方法之间的离散区间,并非经过统计校准的置信区间。

估算方法

分析师目标价:$341.83
现金流折现法(DCF):$577.79
市盈率法(P/E):$202.71
格雷厄姆成长公式:$180.79
盈利能力价值(EPV):$371.86
合理市净率(P/B):$444.89
股息折现模型(戈登模型):$155.93
P/FFO(运营资金):$528.73
周期中段收益:$1027.21
市销率法(P/S):$4214.84
分析师共识:强力买入 (26B / 8H / 0S)
最近财报超预期:-0.59%

估值指标

市盈率(P/E)

11.25

ROE

14.3%

市净率(P/B)

1.69

P/FCF

-

毛利率

20.6%

ROIC

7.8%

盈利能力雷达图

价值创造(经济护城河)

ROIC

7.8%

WACC

6.5%

ROIC − WACC

+1.2 pp

ROIC 超过资本成本:公司正在为股东创造价值。

基本面分析标准

通过(18)

  • EPS shows upward trend
  • EPS CAGR 13.33%
  • Price CAGR 7.73%
  • ROIC 7.7%
  • P/B Ratio 1.69
  • Debt/Equity ratio
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Price below Graham Number
  • ROE 15.2%
  • Revenue Growth 5Y 11.4%
  • Analyst Consensus 76% Buy
  • Earnings Quality (OCF/NI) 1.60
  • Share Dilution -5.2%
  • Net Margin Trend 2.3% vs 1.9%
  • Piotroski F-Score 8/9

未通过(5)

  • Gross Margin 20.6%
  • Operating Margin 3.5%
  • Low reliance on intangibles
  • DCF valuation (Fairly valued)
  • Earnings Surprise avg -0.6%

不可用(5)

  • P/FCF NaN
  • Dividend Payout NaN%
  • Positive Free Cash Flow
  • CapEx intensity
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-评分

8/9

财务状况强健

score
criteria

盈利质量

1.60

高质量:盈利有现金流支撑

股权稀释

-5.2%

正在回购股份,对股东友好

机构持股

公司治理

管理团队

姓名职位年龄
Mr. David Michael CordaniExecutive Chairman of the Board60
Mr. Brian Case Evanko C.F.A.President, CEO & Director48
Ms. Ann M. DennisonExecutive VP & CFO54
Ms. Nicole Susan Jones J.D.Executive Vice President, Chief Administrative Officer & Chief Human Resources Officer54
Mr. F. Everett NevilleExecutive VP & Special Advisor to the CEO60
Ms. Jamie KatesSenior VP & Tax and Global Chief Accounting Officer44
Mr. Durga Prasad KokaExecutive Vice President & Global Chief Information Officer-
Mr. Ralph GiacobbeSenior Vice President of Investor Relations-
Ms. Andrea NelsonEVP, General Counsel & Corporate Secretary-
Ms. Melissa SkottegaardExecutive Vice President, Chief Marketing & Communications Officer-

审计风险

1

董事会风险

4

薪酬风险

7

股东权利风险

7

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

文件

  • 年度报告(10-K)

    对公司业务、财务业绩和风险的年度概述。

    提交日期:2026-02-26

    查看文件
  • 季度报告(10-Q)

    最近三个月财务表现的最新情况。

    提交日期:2026-07-30

    查看文件
  • 临时报告(8-K)

    关于重大事件(如管理层变动或重要公告)的通知。

    提交日期:2026-09-30

    查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for CI, sourced from Markets Gazette.

  • 24d agoNEUTRAL
    Cigna Healthcare on Business Strategy

    Jason Sadler, International Health Global President at Cigna Healthcare, provided insights into the company's business strategy, addressing the dual forces of increasing AI adoption and escalating healthcare expenditures. While the discussion highlights Cigna's navigation of these significant industry trends, it does not present specific financial figures or forward-looking guidance that would indicate a definitive positive or negative impact on the company's immediate stock performance. Investors will monitor Cigna's strategic execution in response to these evolving market dynamics.

  • 5/22/2026NEUTRAL
    Here's How Much You Would Have Made Owning Cigna Group Stock In The Last 20 Years

    An analysis of The Cigna Group's stock performance over the past two decades reveals a significant historical return for investors. While specific figures are not detailed in this summary, the article implies substantial long-term gains. This historical perspective is crucial for investors evaluating Cigna's potential for future growth and stability, offering insights into its resilience and market position through various economic cycles. The focus remains on past performance rather than current catalysts.

  • 3/6/2026POSITIVE
    Here's How Much $1000 Invested In Cigna Group 15 Years Ago Would Be Worth Today

    An investment of $1000 in Cigna Group 15 years ago would have grown to approximately $10,500 today, representing a substantial return on investment. This performance highlights the company's long-term growth trajectory and its ability to generate significant shareholder value over an extended period. Investors who held Cigna stock through various market cycles would have benefited from its strategic initiatives and market positioning within the health insurance and services sector. The impressive growth suggests a robust business model and effective management.

  • 3/3/2026NEGATIVE
    Cigna Stock Falls After CEO Retirement Announcement

    Shares of The Cigna Group (NYSE:CI) experienced a significant decline on Tuesday, following the announcement of CEO David Cordani's retirement. The news immediately triggered a negative market reaction, highlighting investor sensitivity to leadership changes in major corporations. Cordani, a key figure for the healthcare giant, leaves a void that generates uncertainty about the company's future strategic and operational direction. Analysts suggest that the leadership transition could lead to a period of volatility for the stock, as the market awaits clarity on subsequent plans and the identity of the successor. For investors, this event underscores the importance of managerial stability in complex sectors like healthcare.

  • 3/3/2026NEUTRAL
    Cigna’s longtime CEO to step down as health insurers face growing scrutiny

    Cigna Group, a major player in the health insurance sector, has announced a significant leadership transition. David Cordani, who has served as CEO for an impressive 27 years, will step down. He will be succeeded by Brian Evanko, a seasoned company veteran, ensuring a degree of continuity in leadership. This change comes at a time when health insurers are facing increased scrutiny, adding complexity to the new CEO's mandate. For investors, the appointment of an internal successor like Evanko suggests a focus on stability and a continuation of existing strategies, potentially mitigating immediate market volatility. However, the broader industry challenges mean Evanko will need to navigate a demanding regulatory and competitive landscape, making his strategic direction crucial for Cigna's future performance.

via Markets Gazette